Image 1SpecificationsOrganism/cell line/tissue\
Genome or genomic data originHumanSex\
Male or femaleFemaleSequencer or array type\
Type of sequencerIllumina HiSeq 2000 (RNA-seq), Affymetrix Human Transcriptome Array 2.0 GeneChip (Microarray)Data format\
Raw or analyzedRaw data: fastq files (RNA-seq), CEL files (Microarray); Processed data: bam files (RNA-seq), CHP files (Microarray)Experimental factors\
Tumor vs. normal, any pretreatment of samplesResting CD4 T cell culture vs Activated CD4 T cell culture (Total RNA, U2AF2 RIP RNA); U2AF1 siRNA vs Control siRNA (Total RNA, U2AF2 RIP RNA); SYNCRIP siRNA vs Control siRNA (Total RNA, U2AF2 RIP RNA); ILF2 siRNA vs Control siRNA (Total RNA); SRRM2 siRNA vs Control siRNA (Total RNA)Experimental features\
Very brief experimental descriptionRNA-seq and U2AF2 RIP-seq profiling of Resting and Activated CD4 T cell culture to identify differentially expressed/spliced and U2AF2 differentially bound genes, respectively, upon T cell Activation. Microarray gene expression profiling of Activated CD4 T cell culture to identify differentially expressed/spliced transcripts upon siRNA knockdown of RNA-binding proteins (U2AF1, SYNCRIP, ILF2, and SRRM2) relative to Control siRNA. U2AF2 RIP-chip (microarray) profiling of Activated CD4 T cell culture to identify transcripts differentially bound to U2AF2 upon siRNA knockdown of RNA-binding proteins (U2AF1 and SYNCRIP) relative to Control siRNA.Consent\
Level of consent allowed for reuseData are publically availableSample source location\
City, country of model organismLa Jolla, CA, USA

1. Direct link to deposited data {#s0005}
================================

The deposited data can be found at: <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE62923>.

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. Ethics, consent and permissions {#s0015}
------------------------------------

All the studies in this manuscript were covered by Human Subjects Research Protocols approved by the Institutional Review Board of The Scripps Research Institute. Informed written consent was obtained from all study subjects.

2.2. CD4 + T cell culture and experimental conditions {#s0020}
-----------------------------------------------------

CD4 + T cell cultures were generated with CD4 + T cells isolated from the peripheral blood of normal adult human female donors, as described previously [@bb0005]. Briefly, the purified cells were grown and maintained in RPMI 1640 culture medium (+ 10% FBS, 100 U/ml Penicillin, Mediatech) at 37 °C and 5% CO~2~, activated with Dynabead Human T-Activator CD3/CD28 (Thermo) for 48 h, and cultured in the presence of 30 U/ml of IL2. While kept at a density of 0.5 × 10^6^ to 2 × 10^6^ cells/ml, the cells were expanded for 7 days and aliquoted into freezing media (90% FBS/10% DMSO) for storage at − 80 °C. Thawed aliquots were then expanded for an additional 7 days prior to experimental use.

For all sequencing experiments ([Table 1](#t0005){ref-type="table"}), the CD4 + T cell culture was used to compare "resting" and "activated" states. After thawing and expansion, cells were activated with Dynabead Human T-Activator CD3/CD28 for 48 h to produce the "activated" state, while "resting" cells were cultured unchanged for the same 48 h window.

For all microarray experiments ([Table 2](#t0010){ref-type="table"}), cells were transfected by Amaxa Nucleofection (Lonza) following the manufacturer\'s instructions (program CL-120), with specific siRNA added to a final concentration of 300 nM. Cells were then cultured for 48 h prior to activation, cultured for an additional 24 h and collected. Specific siRNA sequences and product information was previously described [@bb0005].

2.3. U2AF2 RNA binding protein immunoprecipitation (RIP) {#s0025}
--------------------------------------------------------

As described previously [@bb0005], frozen cell pellets were resuspended in RIPA buffer (Sigma) supplemented with RNaseOUT (Thermo), Complete EDTA-free protease inhibitor cocktail tablets (Roche, Inc.), and phosphatase inhibitors. Lysates were sonicated, with insoluble material discarded, supplemented with enzyme inhibitors (RNAse, phosphatase, and protease), and quantified for protein. Lysates were then pre-cleared with mouse IgG-conjugated Protein G beads (Thermo) and incubated with a mouse monoclonal U2AF2 antibody (U4758, Sigma) conjugated to Protein G beads. The beads were then washed, digested with RNAse A, and RNA/Protein complexes were eluted two times.

2.4. Total RNA isolation, RNA-seq {#s0030}
---------------------------------

Total RNA was purified from cell aliquots using the RNeasy purification kit (Qiagen) according to the manufacturer\'s protocol. DNA Digestion was performed on the columns with the RNase-Free DNase Set (Qiagen). The concentration of RNA was measured using the Qubit Fluorometer (Thermo) and RNA quality was visually inspected using the Eukaryote Total RNA Nano chip on the 2100 Bioanalyzer (Agilent). RNA-seq libraries were made using the TruSeq RNA Sample Preparation Kit (Illumina) preceded by a PolyA purification step to select only polyadenylated mRNA. Libraries were pooled (4 samples per pool) and clustered using the Illumina cBot system with TruSeq PE Cluster Kit reagents, followed by sequencing on the Illumina HiSeq 2000 system with TruSeq SBS Kit v3 reagents.

2.5. RIP-seq {#s0035}
------------

The two eluates from each of the U2AF2 RIP samples were pooled and combined with TRIZOL LS reagent to separate the RNA fraction. The RNA was washed, precipitated, and treated with the RNase Free DNase Set (Qiagen) while cleaned up on an RNeasy column. The purified RNA was used as input for Script-Seq v2 RNA-Seq Library Preparation kit (Epicentre) and the protocol was performed according to the manual with the following exceptions: 1) No PolyA purification or rRNA depletion steps were performed; 2) DNA Clean and Concentrator-5 - PCR/DNA clean columns (Zymo Research) were used to isolate the cDNA before the PCR step. Libraries were pooled (6 samples per pool) and clustered using the Illumina cBot system with TruSeq SR Cluster Kit reagents, followed by sequencing on the Illumina HiSeq 2000 system with TruSeq SBS Kit v3 reagents.

2.6. Sequence mapping and normalization {#s0040}
---------------------------------------

Sequencing and post-processing was performed by the TSRI Next Gen Sequencing Core Facility which delivers the raw data as FASTQ files. Initial quality assessment of FASTQ files was performed with FastQC (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>). For quality control purposes, reads with a quality score below 25 (Q \< 25) were removed using fastx_clipper from the FASTX Toolkit (<http://hannonlab.cshl.edu/fastx_toolkit/index.html>). Furthermore, reads containing sequencing adapters were trimmed using Trim Galore (<http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/>). The remaining reads were mapped to the human genome build hg19 using TopHat version 2.0.9 [@bb0010]. Read alignments with low mapping quality (q \< 20) were removed using SAMtools (<http://samtools.sourceforge.net>/) and the markDuplicates function within the Picard suite (<http://picard.sourceforge.net>/) was used to remove optical duplicates. See [Table 3](#t0015){ref-type="table"} for numbers of total sequenced and aligned reads for each sample.

Using the R environment (<http://cran.us.r-project.org>/) and open source packages available from Bioconductor (<http://www.bioconductor.org>/), the aligned reads within each BAM file were assigned to both the exon and gene level definitions of all known genes in hg19 as defined by the Bioconductor package TxDb.Hsapiens.UCSC.hg19.knownGene. Custom scripts were used to generate tables of counts for all samples at both the exon and gene level. For gene level counts, the values were normalized by conversion to FPKM (Fragment Per Kilobase of exon model per million mapped reads, [@bb0015]), which accounts for variation in gene size and total reads in each sample. For RIP-seq experiments, as with any type of pulldown experiment, an additional normalization step would typically entail lowering expression estimates based on subtracting read counts from a replicated specificity control (i.e. non-specific immunoglobulin for the species of the antibody). However, the mouse IgG used as a control for the U2AF2 antibody was unable to co-precipitate any RNA that could be used for generating usable sequencing data. As such, no background subtraction step was performed as part of the analysis.

2.7. RNA-seq differential gene expression and splicing {#s0045}
------------------------------------------------------

Based on previous work [@bb0020], genes with log2(FPKM) values below − 2 in more than half of the samples were removed due to insufficient signal relative to the noise. The read counts for the remaining genes were input into the edgeR package [@bb0025] to measure differential gene expression (FDR \< 0.05). Alternative splicing analysis was performed using AltAnalyze (<http://www.altanalyze.org>/) [@bb0030], which uses the ASPIRE algorithm (default threshold \> 0.2) to determine differential splicing between two groups.

2.8. RIP-seq differential binding {#s0050}
---------------------------------

Prior to testing for significant differences between the two groups in the RIP-seq data, a technical analysis of the data was performed to assess the extent to which a standard RNA-seq analysis pipeline could be used to interpret the RIP-seq data. As discussed in [@bb0005], the overall range of expression values is smaller in the RIP-seq data relative to RNA-seq which results in fewer detectable genes when using the empirically established RIP-seq FPKM threshold of 2. For those genes with usable data, there is consistently greater within-group (WG) variation at all levels of expression in the RIP-seq data relative to the RNA-seq data, while the between-group (BG) variation is similarly distributed ([Fig. 1](#f0005){ref-type="fig"}A, B). For the RIP-seq data, this is further demonstrated by the distribution of the log of the F-scores (BG/WG) as a function of relative expression level ([Fig. 1](#f0005){ref-type="fig"}C, blue line). For RNA-seq, noise (WG) is reduced as expression levels increase resulting in a trend of rising F-scores ([Fig. 1](#f0005){ref-type="fig"}C, red line). For the RIP-seq data, a higher noise floor coupled with the lack of noise reduction as expression increase results in a relatively lower and flat F-score distribution.

Thus, with the understanding that the RIP-seq had diminished power to detect differences between Resting and Activated CD4 + T cells relative to RNA-seq, the standard sequencing analysis pipeline was used. As such, the number of significantly different genes ("differentially bound" to U2AF2) identified by edgeR was lower in the RIP-seq, as demonstrated by the percentage of total genes with FDR p-values below the threshold ([Fig. 1](#f0005){ref-type="fig"}D). Furthermore, there was a lack of power to detect differences at the exon level which precluded an analysis for differential splicing. In order to make specific conclusions about alternatively spliced genes that are bound to U2AF2 during the process of T-cell activation [@bb0005], we looked at the overlap of genes that were alternatively spliced in the RNA-seq data and "differentially bound" or not "differentially bound" in the RIP-seq data.

2.9. Microarrays and RIP-Chip {#s0055}
-----------------------------

To globally identify transcripts regulated by U2AF2 interacting proteins, total RNA was extracted from cells that had been treated with control or specific siRNAs. Specifically, the input into the PLUS kit (Affymetrix) was 1 μg of this DNAse treated total RNA. For RIP-Chip, a U2AF2 RNA-binding protein immunoprecipitation was performed on the U2AF1 and SYNCRIP siRNA treated cells and 125 ng of purified, DNAse treated, RNA from this procedure was used as input for the amplification protocol. Labeled, fragmented cRNA was hybridized on the Human Transcriptome Array 2.0 and scanned to generate CEL files. Three replicate experiments were performed for each group with the exception of the U2AF2 RIP from the control siRNA treated cells which was performed six times. The CEL files were input into the Affymetrix Expression Console software to generate normalized, log-transformed RMA values. Genes were filtered out of downstream analysis if the log2(RMA) expression value was \< 6 in 50% or more of the arrays. The remaining genes were imported into the R environment for differential expression analysis by the limma package (adjusted p-value \< 0.05) [@bb0035], [@bb0040]. For splicing analysis, CEL files were directly input into the AltAnalyze package and the default parameters were used to call differentially spliced genes. To plot examples of significantly differentially spliced transcripts between control siRNA and specific siRNA at the junction and exon level, Splicing Index (SI) values were calculated using the Transcript Analysis Console software (TAC, Affymetrix, Inc.).

2.10. Functional enrichment analysis {#s0060}
------------------------------------

For each list of genes (i.e. differentially expressed, differentially spliced, differentially bound) identified with high throughput experiments, an analysis was performed to identify, pathways, functions, and ontological categories that were significantly enriched. The GO-Elite function (within AltAnalyze) was used to perform enrichment analysis (adjusted p-value \< 0.05) on numerous ontologies and annotation databases including GeneOntology, KEGG, Biomarkers, and Wikipathways. An immune specific ontology called ImmuneMap, was used to identify significantly enriched immune related pathways and functions defined as those whose adjusted p-values were below a threshold of 0.05). The adjusted p-values were calculated using a hypergeometric distribution followed by a multiple testing correction using the Benjamini-Hochberg step-up procedure to control the false discovery rate [@bb0045].

3. Discussion {#s0065}
=============

We describe the generation and analysis of multiple datasets including both Illumina deep RNA sequencing and Affymetrix GeneChip microarray experiments. Sequencing experiments measured transcript and isoform level changes in Activated human CD4 + T cells relative to Resting cells using both total RNA and RNA associated with the splicing factor U2AF2. The whole transcriptome scope of these data allowed for a complete characterization of the activation-induced changes in expression and splicing in this novel CD4 + T cell culture system. The U2AF2 RIP-seq data facilitated identification of the specific subset of genes that are post-transcriptionally regulated by U2AF2 and its interacting partners after T cell activation.

The microarray experiments measured changes in the transcriptome of Activated CD4 + T cells treated with control siRNA or siRNA for specific U2AF2 interacting proteins. The effects of knocking down U2AF1, SRRM2, ILF2, and SYNCRIP were measured with total RNA, while changes in RNA associated with U2AF2 were measured after knockdown of U2AF1 and SYNCRIP. For these data, the subset of genes affected by knockdown was uniquely characterized by the number, identity, and direction of change of the genes in the list. In addition, these characteristics in combination with the list of significantly overrepresented functional categories provided insight into the post-transcriptional regulatory role of each U2AF2 interacting protein as well as context for its interaction with U2AF2 during T cell activation.
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###### 

Summary of type of RNA, replicates, library preparation method, read type, and read depth for each cell state in each sequencing experiment.

Table 1

  State       RNA         Replicates   Library prep    Single/paired   Read depth (mean)
  ----------- ----------- ------------ --------------- --------------- -------------------
  Resting     Total       2            TruSeq          Paired          50 × 10^6^
  Activated   Total       2            TruSeq          Paired          50 × 10^6^
  Resting     U2AF2 RIP   6            Script-Seq v2   Single          39 × 10^6^
  Activated   U2AF2 RIP   6            Script-Seq v2   Single          33 × 10^6^

###### 

Summary of type of RNA, replicates, and high throughput gene expression analysis method for each siRNA knockdown experiment.

Table 2

  siRNA     RNA         Replicates   Gene Exp. Platform (Amp. Kit)
  --------- ----------- ------------ -------------------------------
  Control   Total       3            HTA 2.0 (WT PLUS)
  U2AF1     Total       3            HTA 2.0 (WT PLUS)
  SYNCRIP   Total       3            HTA 2.0 (WT PLUS)
  ILF2      Total       3            HTA 2.0 (WT PLUS)
  SRRM2     Total       3            HTA 2.0 (WT PLUS)
  Control   U2AF2 RIP   6            HiSeq 2000 (Script-Seq v2)
  U2AF1     U2AF2 RIP   3            HiSeq 2000 (Script-Seq v2)
  SYNCRIP   U2AF2 RIP   3            HiSeq 2000 (Script-Seq v2)

###### 

Summary of batch (Run ID), replicate number, cell state, and raw and aligned reads for each sample type analyzed by sequencing.

Table 3

  Sequencing   Run ID   Replicate   State       Raw reads   Aligned reads
  ------------ -------- ----------- ----------- ----------- ---------------
  RNA          R53      1           Resting     93393572    80065567
  RNA          R53      1           Activated   117843824   100589736
  RNA          R53      1           Resting     114655128   97972797
  RNA          R53      1           Activated   116873022   98736926
  RIP          R67      1           Resting     34447112    23443371
  RIP          R67      1           Activated   31498888    26314895
  RIP          R80      1           Resting     32456157    24785103
  RIP          R80      1           Activated   19904038    15811632
  RIP          R91      1           Resting     69100755    28827670
  RIP          R91      1           Activated   34153807    21342545
  RIP          R91      2           Resting     43634669    11331093
  RIP          R91      2           Activated   51557362    14454475
  RIP          R107     1           Resting     28139551    13930714
  RIP          R107     1           Activated   35096072    20586253
  RIP          R107     2           Resting     28380320    22840389
  RIP          R107     2           Activated   27067774    19961774
